Virologic and Serologic Markers of Rapid Progression to AIDS after HIV-1 Seroconversion

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 5, 1996, Pages 448-455

  Farzadegan, Homayoon ^a   Henrard, Denis R ^a,b   Kleeberger, Cynthia A ^a   Schrager, Lewis ^c   Kirby, Alison Jill ^a   Saah, Alfred J ^a   Rinaldo Jr , Charles R ^d   O'Gorman, Maurice ^e   Detels, Roger ^f,g   Taylor, Ellen ^a   Phair, John P ^e   Margolick, Joseph B ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f University of Los Angeles   (United States)

^g Tarry Bldg   (United States)

Author keywords

Anti gag immune response; HIV 1; Progression; Seroconversion; Viral load

Indexed keywords

ALPHA INTERFERON; ANTIGEN P24; BETA 2 MICROGLOBULIN; GAG PROTEIN; NEOPTERIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE TRANSMISSION; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA ANALYSIS; SEROCONVERSION; SEXUAL BEHAVIOR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BIOPTERIN; COHORT STUDIES; DISEASE PROGRESSION; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV SEROPOSITIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; INTERFERON-ALPHA; MALE; NEOPTERIN; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030472602     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199612150-00008     Document Type: Article

References (55)

1. Isaksson B, Albert J, Chiodi F, Furucrona A, Krook A, Putkonen P. AIDS two months after primary human immunodeficiency virus infection. J Infect Dis 1988;158:866-7.
2. Munoz A, Kirby AJ, He YD, et al. Long term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr 1995;8:496-505.
3. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992;340:863-7.
4. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
5. Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 1987;138:1064-7.
6. Albert J, Abrahamsson B, Nagy K. Rapid development of isolate-specific neutralizing antibodies after primary-HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1991;4:107-12.
7. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-6.
8. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-56.
9. Ariyoshi K, Harwood E, Chiengsong-Popov R, Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralizing antibodies? Lancet 1992;340:1257-8.
10. Safrit JT, Andrews CA, Zhu T, Ho DD, Koup RA. Characterization of HIV-1 specific CTL close isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope. J Exp Med 1994;179:463-72.
11. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: Long-term HIV-1 infection with stable CD4+ T-cells levels. J Acquir Immune Defic Syndr 1993;7:1159-66.
12. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
13. Kaslow R, Carrington M, Apple R, et al. Influence of combinations of major histocpmpatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-11.
14. Kaslow RA, Mann DL. The role of the major histocompatibility complex in human immunodeficiency virus infection - ever more complex. J Infect Dis 1994;169:1332-3.
15. Farzadegan H, Chmiel JS, Odaka N, et al. Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number, and AIDS-free time. J Infect Dis 1992;166:1217-22.
16. Lange JMA, Paul DA, Huisman G, et al. Persistent HIV antigenemia and decline of HIV core antibodies associated with transition to AIDS. Er Med J 1986;295:1459-62.
17. Allain JP, Laurian Y, Paul DA, et al. Long-term evaluation of HIV antigen and antibodies to p25 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med 1987;317:1114-21.
18. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:S3-15.
19. Chmiel JS, Detels R, Kaslow RA, VanRaden M, Kingsley LA, Brookmeyer R. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987;126:568-77.
20. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:14-24.
21. Gallarda JL, Henrard DR, Liu D, et al. Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody. J Clin Microbiol 1992;30:2379-84.
22. Kageyama S, Yamada C, Mohammad S-S, et al. An improved method for the detection of HIV antigen in the blood of carriers. J Virol Methods 1988;22:125-31.
23. Henrard DR, Wu S, Phillips J, Wiesner D, Phair J. Detection of p24 antigen with and without immune complex dissociation (ICD) for longitudinal monitoring of HIV-1 infection. J Clin Microbiol 1995;33:72-5.
24. Henrard DR, Mehaffey WF, Allain IP. Sensitive viral capture assay for detection of plasma viremia in HIV infected individuals. AIDS Res Hum Retroviruses 1992;8:47-50.
25. Coombs RW, Henrard DR, Mehaffey WF, et al. Cell-free plasma HIV-1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J Clin Microbiol 1993;30:1980-6.
26. Lin HJ, Myers LE, Yeu-Lieberman B, Hollinger FB, Henrard D, Hooper CJ, Kokka R, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:553-62.
27. Ferbas JJ, Toso JF, Logar AJ, Navratil JS, Rinaldo CR. CD4+ blood dendritic cells are potent producers of INF-α in response to in vitro HIV-1 infection. J Immunol 1994;152:4649-62.
28. Check IJ, Piper M, Papadea C. Immunoglobulin quantitation. In: Rose NR, deMacario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology, 4th ed. Washington: American Society for Microbiology, 1976:71-83.
29. Giorgi JV, Cheng H-L, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter Aids Cohort study (MACS) experience. Clin Immunol Immunopathol 1990;55:173-86.
30. Munoz A, Wang M-C, Bass S, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Am J Epidemiol 1989;130:530-9.
31. Phair JP, Jacobson L, Detels R, et al. Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1992;5:490-6.
32. Hofmann B, Wang YX, Cumberland WG, Detels R, Bozorgmehri M, Fahey JL. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS 1990;4:207-14.
33. Lee T-H, Sheppard HW, Reis M, Dondero D, Osmond D, Busch MP. Circulating HIV-1 infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune Defic Syndr 1994;7:381-8.
34. Keet I, Krijnen P, Koot M, Lange J, Miedema F, Goudsmit J, Coutinho R. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7:51-7.
35. Zwart G, Van Der Hoek L, Valk M, et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 1994;201:285-93.
36. McDougal JS, Kennedy MS, Nicholson JKA, et al. Antibody response to human immunodeficiency virus in homosexual men. J Clin Invest 1987;80:316-24.
37. Allain JP, Laurian Y, Einstein MH, et al. Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance. Blood 1991;77:1118-23.
38. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Arosstam A, Wadsworth J, Weber J. Relation between responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. Br Med J 1991;302:23-6.
39. Lange JMA, deWolf F, Krone WJA, Danner SA, Coutinho RA, Goudsmit J. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS 1987;1:155-9.
40. Williams LM, Cloyd MW. Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology 1991;184:723-8.
41. Henrard DR, Daar E, Farzadegan H, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:305-11.
42. Chakrabarti L, Cumont M-C, Montagnier L, Hurtrel B. Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression. J Virol 1994;68:6634-42.
43. Koup RA, Pikora CA, Luzuriaga K, et al. Limiting dilution analysis of CTL to HIV gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J Exp Med 1991;174:1593-600.
44. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in patients with primary HIV-1 infection. N Engl J Med 1991;324:954-60.
45. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-2.
46. Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 1991;4:704-12.
47. Clerici M, Shearer GM. A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-11.
48. Pezzo HIP, Phillips AN, Dorrucci M, Cozzi Lepri N, Vlahov D. HIV exposure category and age in the progression to AIDS in a longitudinal study of 1199 individuals with known seroconversion dates. Br Med J 1996;310:941-8.
49. Phillips AN, Lee CA, Elford J, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991;4:970-5.
50. Blaxhult A, Granath F, Lidman K, Giesecke J. The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990;4:125-9.
51. Goedert J, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989;321:1141-8.
52. Kopec-Schrader E, Tindall B, Learmont J, Wylie B, Kaldor J. Development of AIDS in people with transfusion-acquired HIV infection. AIDS 1993;7:1009-13.
53. Veugelers PJ, Page KA, Tindall B, et al. Determinants of HIV disease progression among homosexual men registered in the tricontinental seroconverter study. Am J Epidemiol 1994;140:747-58.
54. Biggar RJ and the International Registry of Seroconverters. AIDS incubation in 1,891 HIV seroconverters from different exposure groups. AIDS 1990;4:1059-66.
55. Walker MC, Fast PE. Clinical trials of candidate AIDS vaccine. AIDS 1994;8:S213-36.